Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL

Study identifier:D133HR00022

ClinicalTrials.gov identifier:NCT05958134

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL: Multicenter Retrospective Study (Real World Evidence – RWE)

Medical condition

Diffuse Large B Cell Lymphoma

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

600

Study type

Observational

Age

18 Years - 100 Years

Date

Study Start Date: 15 Jul 2023
Primary Completion Date: 06 Jun 2024
Study Completion Date: 06 Jun 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Hospital Israelita Albert Einstein

Inclusion and exclusion criteria